We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Effectiveness, safety, and heart-related results of once-daily oral semaglutide in people with type 2 diabetes
AI simplified
Abstract
Oral semaglutide 7 and 14 mg once daily significantly reduced glycated haemoglobin () and body weight in patients with type 2 diabetes over treatment periods of up to 78 weeks.
- Oral semaglutide was tested in patients with type 2 diabetes with a duration of 3.5 to 15 years.
- The treatment showed better efficacy than placebo and standard glucose-lowering medications, including sitagliptin and empagliflozin.
- Patients experienced improvements in other diabetes-related endpoints, such as fasting plasma glucose.
- Oral semaglutide was well tolerated, with transient gastrointestinal events being the most common side effects.
- Cardiovascular safety was confirmed for oral semaglutide in patients with cardiovascular disease or high cardiovascular risk.
AI simplified
Key numbers
−1.0%
Reduction
Change in for oral semaglutide vs. placebo in PIONEER 6.
−4.2 kg
Weight Loss
Mean weight reduction with oral semaglutide vs. placebo in patients with cardiovascular disease.
80%
Trial Completion Rate
Percentage of patients completing the PIONEER trials.